Resources
5 Results (showing 1 - 5)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 7/28/2020 (updated 3/28/2024)
Brandeis University’s Institute for Behavioral Health Opioid Policy Research Collaborative launched the Brandeis Opioid Resource Connector (BORC) website, a comprehensive online resource for communities and local leaders addressing the opioid crisis.
Posted 3/23/2022 (updated 3/27/2024)
The JBS evaluation team will review and provide guidance on the PIMS measures that are most problematic for grantees and the new PIMS measures that are pending OMB approval. They will also highlight ways that consortiums can use their data dashboards to highlight successes and areas for improvement as they work to obtain funding and motivate and engage stakeholders.
Posted 7/21/2023 (updated 3/28/2024)
A recent study, Stigmatizing Imagery For Substance Use Disorders: A Qualitative Exploration, explored the use of stigmatizing and non-stigmatizing imagery in the field of substance use disorders and law enforcement. While the discussion of stigmatizing language has been around, the discussion of stigmatizing imagery is important to have as it may have effects on treatment, recovery, and reintegration. The qualitative study interviewed people with lived substance use disorder experience who identified stigmatizing imagery and the possible implications it could have.
Posted 7/28/2023 (updated 3/26/2024)
Researchers interviewed 20 individuals – clinicians, peer support specialists, cultural practitioners, and others familiar with OUD treatment – in a Minnesota tribal community. The Cascade of Care model measures the quality of outcomes at each stage of treatment, from diagnosis to long-term maintenance, and was first proposed in 1998 as an approach to care for HIV/AIDS.
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.